Showing 5401-5410 of 5909 results for "".
- Optovue to Introduce NetVue Cloud Image Management Solutions at AAOhttps://modernod.com/news/optovue-introduces-netvue-cloud-image-management-solutions-at-aao/2476940/Optovue announced it will introduce NetVue Cloud image management software at the annual AAO meeting in San Francisco. The NetVue software provides quick access to patients’ images and data on a single screen, eliminating the need to open device-specific app
- DORC Obtains 510k Clearance for Launch of EVA Upgrade Enhancementshttps://modernod.com/news/dorc-obtains-510k-clearance-for-launch-of-eva-upgrade-enhancements/2476922/DORC has announced 510(k) clearance for a range of enhancements to the EVA surgical system. The enhancements has been developed in close collaboration with surgeons and deliver both OR efficiency and surgical performa
- Clinreg Consulting Services Appoints New President and Plans to Expand Consulting Teamhttps://modernod.com/news/clinreg-consulting-services-appoints-new-president-and-plans-to-expand-consulting-team/2476920/Clinreg Consulting Services, a provider of regulatory, clinical, statistical, data management, and quality consulting services, announced the appointment of Lee Kramm, MD, MSE, as President and plans to expand its con
- Eversight to Offer Preloaded DMEK in DORC Tubehttps://modernod.com/news/eversight-first-to-offer-preloaded-dmek-in-dorc-tube/2476911/Eversight announced it is the first eye bank to prepare preloaded Descemet membrane endothelial keratoplasty (DMEK) tissue in the Melles DORC tube, offering corneal surgeons more preloaded tissue options that further streamline surgeries and reduce cost, according to a company news release. <
- GenSight Biologics Reports Sustained Efficacy and Safety at 96 Weeks in RESCUE Phase 3 Trial of GS010 for the Treatment of LHONhttps://modernod.com/news/gensight-biologics-reports-sustained-efficacy-and-safety-at-96-weeks-in-rescue-phase-3-trial-of-gs010-for-the-treatment-of-lhon/2476910/GenSight Biologics reported the first set of results from week 96 of the RESCUE phase 3 clinical trial, which evaluated the efficacy and safety of a single intravitreal injection of GS010 (rAAV2/2-ND4) in 39 subjects whose visual loss due to 11778-ND4 Leber Hereditary Optic Neuropat
- Sifi Appoints New Country Manager for Italyhttps://modernod.com/news/sifi-appoints-new-country-manager-for-italy/2476904/Sifi has announced that Fabrizio Folco has joined the company as “Country Manager Italy,” and will be responsible for accelerating company development on the Italian market through management of the company’s commercial strategy and organization, for both pharma and surgical are
- Eye Cancer Researchers at Bascom Palmer and Sylvester Identify Function of Key Tumor Suppressorhttps://modernod.com/news/eye-cancer-researchers-at-bascom-palmer-and-sylvester-identify-function-of-key-tumor-suppressor/2476900/Cancer cells remember things they shouldn’t. During development, stem and progenitor cells move freely through the body as they differentiate into heart, brain, liver, and eyes. But after humans are born, that process should stop. Cells shouldn’t travel or change anymore; they should stay put and
- Schwind Introduces Schwind ATOS Femtosecond Laser With SmartSighthttps://modernod.com/news/schwind-introduces-new-schwind-atos-femtosecond-laser-with-smartsight/2476899/Schwind eye-tech-solutions has introduced a new femtosecond laser, Schwind ATOS, which features an advanced minimally invasive lenticule extraction called the SmartSight procedure. Featuring intelligent eye tracking w
- Compulink Launches E-Commerce Solution for its All-in-One Optometry EHR at Vision Expo Westhttps://modernod.com/news/compulink-launches-e-commerce-solution-for-its-all-in-one-optometry-ehr-at-vision-expo-west/2476895/Compulink Healthcare Solutions will officially unveil its MyEyeStore e-commerce solution at Vision Expo West from September 19-21, 2019 in Las Vegas. MyEyeStore allows eye care practices to offer their patients the ability to order contact lenses and other recommended products directly fro
- Phase 2 Study Highlights Efficacy and Safety Data of Intravitreal APL-2 for Geographic Atrophy Secondary to AMDhttps://modernod.com/news/phase-2-study-highlights-efficacy-and-safety-data-of-intravitreal-apl-2-for-geographic-atrophy-secondary-to-amd/2476891/Apellis Pharmaceuticals announced details about its phase 2 FILLY study investigating intravitreal (IVT) APL-2 (pegcetacoplan) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) have been published in Ophth